Clinical Trial: Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer

U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT06809426) titled 'Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer' on Jan. 23.

Brief Summary: Evaluating the safety and antitumor efficacy of 177Lu-LNC1011

Study Start Date: Aug. 21, 2023

Study Type: INTERVENTIONAL

Condition: PSMA PET-Positive Castration-Resistant Prostate Cancer

Intervention: DRUG: 177Lu-LNC1011

75 mCi (2.78 GBq) of 177Lu-LNC1011 Injection intravenously each time, injections every 6 weeks, not to exceed a total of 6 injections.

Recruitment Status: COMPLET...